CorMedix completed the acquisition of Melinta Therapeutics from Deerfield Management Company for $325m.

CorMedix, a public biopharma company, completed the acquisition of Melinta Therapeutics, a commercial-stage biopharmaceutical company, from Deerfield Management Company, a private equity firm, for $325m. “This acquisition represents a milestone achievement for Melinta and validates our position as a recognized leader in acute care. I'm incredibly proud of our accomplishnts. Through our talented team's dedication, we have undergone amen extraordinary transformation to build a highly sought-after commercialization platform with sustainable growth and profitability. By joining forces with CorMedix, we're creating a stronger organization that will accelerate both our mission to provide innovative therapies to people impacted by acute and life-threatening illnesses and our vision that all patients who need our therapies receive them,” Christine Ann Miller, Melinta Therapeutics CEO.